Aridis Pharmaceuticals Debt 2024

Aridis Pharmaceuticals Aktienanalyse

What does Aridis Pharmaceuticals do?

Aridis Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of immunotherapeutics and antibiotics for the treatment of infectious diseases. It was founded in 2003 in San Jose, California. The company's business model aims to address the gap in the infectious disease market caused by antibiotic resistance and the lack of new therapy options. Aridis has developed several patented technologies that allow for the quick and effective identification of potential candidates for new therapies. The company focuses on antibiotic development, utilizing a library of human monoclonal antibodies targeted specifically for infectious diseases. These antibodies can be used to target bacteria and achieve better efficacy against antibiotic resistance. Aridis has promising candidates in clinical development. The company also focuses on the development of immunotherapeutics for infectious diseases. They have developed a portfolio of monoclonal antibodies that target pathogenic microbes and can activate immune cells to strengthen the body's immune system. Some of Aridis' key products include Aerucin for the treatment of pneumonia and other respiratory diseases, and AR-101 for severe infections caused by Pseudomonas aeruginosa. Both products are currently in Phase II of development. Another important product is AR-301, a monoclonal antibody developed for the treatment of severe Staphylococcus infections. AR-301 has successfully completed Phase IIb studies and is currently undergoing accelerated approval by the US Food and Drug Administration (FDA). Aridis has formed collaborations with academic institutions and other biopharmaceutical companies to access the latest scientific knowledge and technologies. They have partnerships with multiple universities and research institutes worldwide. The company has also partnered with AmpliPhi Biosciences for the development of bacteriophage-based therapies for infectious diseases, and with Mount Sinai Health System for the development of immunotherapeutics for respiratory diseases. Overall, Aridis has a strong position in the infectious disease market and is well-positioned to address the gap caused by antibiotic resistance and the lack of new therapies. With a strong portfolio of patented technologies, promising candidates in clinical development, and broad partnerships, the company has the potential to become a leading player in the industry. Aridis Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Aridis Pharmaceuticals's Debt Structure

Aridis Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Aridis Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Aridis Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Aridis Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Aridis Pharmaceuticals Stock

What is the debt of Aridis Pharmaceuticals this year?

Aridis Pharmaceuticals has a debt level of -4.36 USD this year.

What was the debt of Aridis Pharmaceuticals compared to the previous year?

The debt of Aridis Pharmaceuticals has increased by -64.05% compared to the previous year dropped.

What are the consequences of high debt for investors in Aridis Pharmaceuticals?

High debt can pose a risk for investors of Aridis Pharmaceuticals, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Aridis Pharmaceuticals?

Low debt means that Aridis Pharmaceuticals has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Aridis Pharmaceuticals affect the company?

An increase in debt of Aridis Pharmaceuticals can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Aridis Pharmaceuticals affect the company?

A reduction in debt of Aridis Pharmaceuticals can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Aridis Pharmaceuticals?

Some factors that can influence the debt of Aridis Pharmaceuticals include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Aridis Pharmaceuticals so important for investors?

The debts of Aridis Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Aridis Pharmaceuticals take to change the debt?

To change the debt, Aridis Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Aridis Pharmaceuticals pay?

Over the past 12 months, Aridis Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aridis Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aridis Pharmaceuticals?

The current dividend yield of Aridis Pharmaceuticals is .

When does Aridis Pharmaceuticals pay dividends?

Aridis Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aridis Pharmaceuticals?

Aridis Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aridis Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aridis Pharmaceuticals located?

Aridis Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aridis Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aridis Pharmaceuticals from 6/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/9/2024.

When did Aridis Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/9/2024.

What was the dividend of Aridis Pharmaceuticals in the year 2023?

In the year 2023, Aridis Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aridis Pharmaceuticals pay out the dividend?

The dividends of Aridis Pharmaceuticals are distributed in USD.